What is the medical insurance coverage of tepotinib in 2024? Are there any generic drugs on the market in Laos?

Since Tepotinib was launched in China in 2023, this innovative targeted treatment drug for non-small cell lung cancer (NSCLC) patients with MET gene exon 14 skipping mutations has been attracting the attention of patients and the medical community. Among them, its medical insurance coverage and the launch of generic drugs have become hot topics of concern to the majority of patients.

First of all, as far as the medical insurance coverage of tepotinib is concerned, it has not yet been included in China’s national medical insurance directory. This means that patients need to pay the full amount out of pocket when purchasing and using this drug, which undoubtedly puts greater financial pressure on patients who require long-term treatment. However, as the country continues to improve the medical security system and gradually adjusts pharmaceutical policies, tepotinib is expected to be included in the medical insurance catalog in the future, thereby providing patients with more financial support and protection.

So, faced with the high cost of original drugs, do patients have more economical treatment options? This involves the issue of generic drugs. In terms of generic drugs, the good news is that Lao ASEAN Pharmaceuticals has successfully launched a generic version of tepotinib and is already on the market. The specification of this generic drug is 225mg*60 tablets, and the price is about more than 9,000 yuan per box. Compared with the price of the original drug, it is indeed more affordable. In addition, the Lucius version of Laos has also launched a generic version of tepotinib, which is more affordable at about more than 7,000 yuan per box, which further reduces the cost of treatment for patients.

However, patients also need to pay attention to some issues when choosing to purchase generic drugs. First of all, be sure to choose formal channels to purchase to ensure the quality and safety of medicines. Secondly, as a prescription drug, the use of tepotinib must strictly follow the guidance of a professional doctor or pharmacist. Before considering using tepotinib, patients should consult a medical professional in detail to ensure that the selected drug matches their condition and treatment needs, and they should use the drug rationally and strictly in accordance with the doctor's instructions.

In short, although tepotinib is not currently covered by China's national medical insurance, the emergence of generic drugs on the market will undoubtedly provide a more economical and affordable option for patients in need of treatment. However, when purchasing and using these generic drugs, patients must pay attention to whether the source of the drugs is regular to ensure their quality and safety. At the same time, patients should use drugs scientifically and rationally under the guidance of professional medical personnel, such as doctors or pharmacists, to ensure therapeutic effects.